Show simple item record

dc.creatorFigueroa Protti, Lucía
dc.creatorSoto Molinari, Rebeca
dc.creatorCalderón Osorno, Melany
dc.creatorMora Rodríguez, Javier Francisco
dc.creatorAlpízar Alpízar, Warner
dc.date.accessioned2019-10-18T19:38:55Z
dc.date.available2019-10-18T19:38:55Z
dc.date.issued2019-09-24
dc.identifier.citationhttps://doi.org/10.1155/2019/1079710es_ES
dc.identifier.urihttps://hdl.handle.net/10669/79405
dc.description.abstractGastric cancer (GC) is one of the most important malignancies worldwide because of its high incidence and mortality. The very low survival rates are mainly related to late diagnosis and limited treatment options. GC is the final clinical outcome of a stepwise process that starts with a chronic and sustained inflammatory reaction mounted in response to Helicobacter pylori infection. The bacterium modulates innate and adaptive immunity presumably as part of the strategies to survive, which favors the creation of an immunosuppressive microenvironment that ultimately facilitates GC progression. T-cell exhaustion, which is characterized by elevated expression of immune checkpoint (IC) proteins, is one of the most salient manifestations of immunosuppressive microenvironments. It has been consistently demonstrated that the tumor-immune microenvironment(TIME)‐exhausted phenotype can be reverted by blocking ICs with monoclonal antibodies. Although these therapies are associated with long-lasting response rates, only a subset of patients derive clinical benefit, which varies according to tumor site. The search for biomarkers to predict the response to IC inhibition is a matter of intense investigation as this may contribute to maximize disease control, reduce side effects, and minimize cost. The approval of pembrolizumab for its use in GC has rocketed immuno-oncology research in this cancer type. In this review, we summarize the current knowledge centered around the immune contexture and recent findings in connection with IC inhibition in GC.es_ES
dc.language.isoen_USes_ES
dc.sourceJournal of Oncology, Volume 2019, Article ID 1079710, 11 pageses_ES
dc.subjectcanceres_ES
dc.titleGastric cancer in the era of immune checkpoint blockadees_ES
dc.typeartículo científicoes_ES
dc.identifier.doi10.1155/2019/1079710
dc.description.procedenceUCR::Vicerrectoría de Investigación::Unidades de Investigación::Ciencias Básicas::Centro de Investigación en Estructuras Microscópicas (CIEMIC)es_ES
dc.description.procedenceUCR::Vicerrectoría de Docencia::Salud::Facultad de Microbiologíaes_ES
dc.description.procedenceUCR::Vicerrectoría de Investigación::Unidades de Investigación::Ciencias de la Salud::Instituto de Investigaciones en Salud (INISA)es_ES
dc.description.procedenceUCR::Vicerrectoría de Investigación::Unidades de Investigación::Ciencias de la Salud::Centro de Investigación en Enfermedades Tropicales (CIET)es_ES
dc.description.procedenceUCR::Vicerrectoría de Docencia::Salud::Facultad de Medicina::Escuela de Medicinaes_ES
dc.identifier.codproyecto810-B9-108


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record